Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 6/20 | 0.71 |
| ▸ | KLKB1 known ✓ | P03952 | 2/20 | 0.55 |
| ▸ | F10 | P00742 | 18/20 | 0.71 |
| ▸ | F2 | P00734 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL254113 | 0.99 | F10 (0.72) | F10KCNH2F2KLKB1 | |
| SCHEMBL6694260 | 0.89 | KCNH2 (0.64) | F10KCNH2F2KLKB1 | |
| SCHEMBL805112 | 0.89 | RAB9A (0.58) | F10KCNH2F2 | |
| SCHEMBL890632 | 0.88 | F10 (0.71) | F10KCNH2KLKB1 | |
| SCHEMBL890676 | 0.88 | F10 (0.74) | F10KCNH2KLKB1 | |
| SCHEMBL14366426 | 0.88 | F10 (0.58) | F10KCNH2F2 | |
| SCHEMBL890791 | 0.88 | F10 (0.57) | F10KCNH2F2 | |
| SCHEMBL10177863 | 0.88 | F10 (0.57) | F10KCNH2F2 | |
| SCHEMBL6694262 | 0.87 | F10 (0.63) | F10KCNH2F2KLKB1 | |
| SCHEMBL28126263 | 0.87 | F10 (0.57) | F10KCNH2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190046510-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. | 2019-02-14 | — | — | US | disclosed |
| US-20170326119-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. | 2017-11-16 | — | — | US | disclosed |
| US-9555023-B2 | Pharmaceutical salts and polymorphs of a factor Xa inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| EP-2611779-B1 | CRYSTALLINE FORMS OF A FACTOR Xa INHIBITOR | PORTOLA PHARM INC (US) | 2016-08-10 | — | — | EP | disclosed |
| CN-105732490-A | Preparation method of betrixaban | 重庆医科大学 | 2016-07-06 | — | — | CN | disclosed |
| US-20160101089-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. | 2016-04-14 | — | — | US | disclosed |
| US-9221758-B2 | Methods of synthesizing pharmaceutical salts of a factor Xa inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| EP-2404906-B1 | Methods of synthesizing pharmaceutical salts of a factor XA inhibitor | MILLENNIUM PHARM INC (US) | 2015-07-15 | — | — | EP | disclosed |
| US-9061019-B2 | Pharmaceutical salts and polymorphs of a factor Xa inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| CN-102336702-B | Pharmaceutical salts and polymorphs of a factor XA inhibitor n-(5-chloro-pyridin-2-yl)-2-(4-cyano-benzoyl-amino)-5-methoxy-benzamide hydrochloride | MILLENNIUM PHARM INC | 2015-02-11 | — | — | CN | disclosed |
| US-20100063113-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. | 2010-03-11 | — | — | US | disclosed |
| US-7598276-B2 | Better thermal and hydrolytic stability than the free-base compounds; N-(5-chloro-pyridin-2-yl)-2-(4-cyano-benzoyl-amino)-5-methoxy-benzamide Hydrochloride | MILLENIUM PHARMACEUTICALS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| EP-2101760-A2 | UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH AN ORAL FACTOR XA INHIBITOR | Millennium Pharmaceuticals, Inc. (US) | 2009-09-23 | — | — | EP | disclosed |
| EP-2077995-A1 | METHODS OF SYNTHESIZING PHARMACEUTICAL SALTS OF A FACTOR XA INHIBITOR | Millennium Pharmaceuticals, Inc. (US) | 2009-07-15 | — | — | EP | disclosed |
| EP-1948608-A2 | PHARMACEUTICAL SALTS AND POLYMORPHS OF N-(5-CHLORO-2-PYRIDINYL)-2-[[4-[(DIMETHYLAMINO)IMINOMETHYL]BENZOYL]AMINO]-5-METHOXY-BENZAMIDE , A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20080153876-A1 | Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor | MILLENNIUM PHARMACEUTICALS, INC. | 2008-06-26 | — | — | US | disclosed |
| WO-2008073670-A2 | UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH AN ORAL FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008057972-A1 | METHODS OF SYNTHESIZING PHARMACEUTICAL SALTS OF A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2007056517-A2 | PHARMACEUTICAL SALTS AND POLYMORPHS OF N- (5-CHL0R0-2-PYRIDINYL) -2- [ [4- [ (DIMETHYLAMINO) IMINOMETHYL] BENZOYL] AMINO] -5-METH OXY-BENZAMIDE, A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070112039-A1 | Better thermal and hydrolytic stability than the free-base compounds; N-(5-chloro-pyridin-2-yl)-2-(4-cyano-benzoyl-amino)-5-methoxy-benzamide Hydrochloride | MILLENNIUM PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326119-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR | F12, F11, TFPI | KCNH2 3549/4885KLKB1 177/4885F10 10/4885 |
| US-20190046510-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR | F12, F11, TFPI | KCNH2 3549/4885KLKB1 177/4885F10 10/4885 |
| US-20070112039-A1 | Better thermal and hydrolytic stability than the free-base compounds; N-(5-chloro-pyridin-2-yl)-2-(4-cyano-benzoyl-amino)-5-methoxy-benzamide Hydrochloride | F12, CMA1, F11 | KCNH2 741/4885KLKB1 268/4885F10 10/4885 |
| US-20080153876-A1 | Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor | SERPINC1, TFPI, F11 | KCNH2 4230/4885KLKB1 78/4885F10 6/4885 |
| US-20100063113-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR | F12, F11, TFPI | KCNH2 3549/4885KLKB1 177/4885F10 10/4885 |
| US-20160101089-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR | F12, F11, TFPI | KCNH2 3549/4885KLKB1 177/4885F10 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.